Ferguson Enterprises Inc. Common Stock vs ImmunityBio Inc. Common Stock — how do they compare? Ferguson Enterprises Inc. Common Stock trades at $222.36 (market cap $43.13B), while ImmunityBio Inc. Common Stock trades at $10 (market cap $10.50B). The key difference: Ferguson Enterprises Inc. Common Stock is far larger — about 4.1× ImmunityBio Inc. Common Stock's market cap, and Ferguson Enterprises Inc. Common Stock pays a 1.6% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferguson Enterprises Inc. Common Stock for 0 Days and ImmunityBio Inc. Common Stock for 6 Days on average.
| FERG | IBRX | |
|---|---|---|
Market Cap | $43.13B | $10.50B |
Volume | 1,358,634 | 30,068,214 |
Sector | Industrials | Health |
52-Week High | $267.71 | $11.55 |
52-Week Low | $214.26 | $1.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $49.58B | $10.96B |
Dividend Yield | 1.6% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Ferguson Enterprises, Inc. distributes plumbing, HVAC, waterworks, and related building products to professional contractors, builders, and facility managers across North America, operating through branches, showrooms, and digital commerce.
Read more on FERG →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →